MedTrace Logo

Antibody Persistence, Immune Response and Safety After Doses of Pentabio Vaccine

NCT02095314 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 399

Last updated 2014-12-18

No results posted yet for this study

Summary

Measure antibody persistence prior to booster administration of Pentabio vaccine.

Conditions

  • Healthy

Interventions

BIOLOGICAL

Pentavalen

Batch 5010613

Sponsors & Collaborators

  • PT Bio Farma

    lead INDUSTRY

Principal Investigators

  • Kusnandi Rusmil, MD · Department of Child Health, School of Medicine Padjadjaran University

  • Hartono Gunardi, MD · Department of Child Health, School of Medicine, University of Indonesia

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Months
Max Age
24 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2014-06-30
Completion
2014-12-31

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02095314 on ClinicalTrials.gov